This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delaugerre, C. Articles by Calvez, V. Search for Related Content PubMed PubMed Citation Articles by Delaugerre, C. Articles by Calvez, V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2002, p. 1586-1588, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1586-1588.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine

Constance Delaugerre,¹ Anne-Geneviève Marcelin,¹ Vincent Thibault,¹ Gilles Peytavin,² Tony Bombled,¹ Marie-Valérie Bochet,^3,4 Christine Katlama,⁴ Yves Benhamou,³ and Vincent Calvez^1*

Departments of Virology,¹ Hepatology,³ Infectious Diseases, Pitié-Salpêtrière Hospital,⁴ Department of Clinical Pharmacology, Bichat-Claude Bernard Hospital, Paris, France²

Received 13 August 2001/ Returned for modification 6 November 2001/ Accepted 22 January 2002

Adefovir dipivoxil (ADV) at a suboptimal concentration for human immunodeficiency virus type 1 (HIV-1) (10 mg once daily) can be used to treat hepatitis B virus (HBV) infection in HIV-1-HBV-coinfected patients and does not, even in the case of uncontrolled HIV-1 replication, select for either ADV mutations at codons 65 and 70 or any other particular HIV-1 reverse transcriptase resistance profile.

---

* Corresponding author. Mailing address: Department of Virology, 83, blvd de l'hôpital, 75013 Paris, France. Phone: 33142177401. Fax: 33142177411. E-mail: vincent.calvez{at}psl.ap-hop-paris.fr.

---

Antimicrobial Agents and Chemotherapy, May 2002, p. 1586-1588, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1586-1588.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., Gatell, J. M., Hirsch, M. S., Katzenstein, D. A., Richman, D. D., Vella, S., Yeni, P. G., Volberding, P. A. (2006). Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel. JAMA 296: 827-843 [Abstract] [Full Text]  
• Kearney, B. P., Ramanathan, S., Cheng, A. K., Ebrahimi, R., Shah, J. (2005). Systemic and Renal Pharmacokinetics of Adefovir and Tenofovir Upon Coadministration. J Clin Pharmacol 45: 935-940 [Abstract] [Full Text]  
• Menne, S., Cote, P. J., Korba, B. E., Butler, S. D., George, A. L., Tochkov, I. A., Delaney, W. E. IV, Xiong, S., Gerin, J. L., Tennant, B. C. (2005). Antiviral Effect of Oral Administration of Tenofovir Disoproxil Fumarate in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. Antimicrob. Agents Chemother. 49: 2720-2728 [Abstract] [Full Text]  
• Rivkin, A. M (2004). Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B. The Annals of Pharmacotherapy 38: 625-633 [Abstract] [Full Text]  
• De Clercq, E. (2003). Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections. Clin. Microbiol. Rev. 16: 569-596 [Abstract] [Full Text]